Related references
Note: Only part of the references are listed.German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients
Kambiz Rahbar et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer
Axel Braeuer et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617
Hojjat Ahmadzadehfar et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
177Lu-PSMA Radioligand Therapy for Prostate Cancer
Wolfgang P. Fendler et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Clinical translation of a PSMA inhibitor for 99mTc-based SPECT
Guillermina Ferro-Flores et al.
NUCLEAR MEDICINE AND BIOLOGY (2017)
99mTc-labeled PSMA inhibitor: Biokinetics and radiation dosimetry in healthy subjects and imaging of prostate cancer tumors in patients
Clara Santos-Cuevas et al.
NUCLEAR MEDICINE AND BIOLOGY (2017)
177Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer
Finn E. von Eyben et al.
ONCOTARGET (2017)
Phase II trial of 177Lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu- J591) in patients (pts) with metastatic castrate-resistant prostate cancer (metCRPC)
S. T. Tagawa et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Pharmacokinetics of Monoclonal Antibodies
Josiah T. Ryman et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
PET/CT with C-11-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data
Stefano Fanti et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)
First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake
Neeta Pandit-Taskar et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer
Maroor Raghavan Ambikalmajan Pillai et al.
NUCLEAR MEDICINE AND BIOLOGY (2016)
A Novel 111In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer
Kristell L. S. Chatalic et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer
Martina Benesova et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies
Martina Weineisen et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
(R)-NODAGA-PSMA: A Versatile Precursor for Radiometal Labeling and Nuclear Imaging of PSMA-Positive Tumors
Eleni Gourni et al.
PLOS ONE (2015)
Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer
Mehdi Evazalipour et al.
CONTRAST MEDIA & MOLECULAR IMAGING (2014)
RNA aptamer-conjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivo
Si Eun Baek et al.
JOURNAL OF CONTROLLED RELEASE (2014)
A Prospective Pilot Study of 89Zr-J591/Prostate Specific Membrane Antigen Positron Emission Tomography in Men with Localized Prostate Cancer Undergoing Radical Prostatectomy
Joseph R. Osborne et al.
JOURNAL OF UROLOGY (2014)
Noninvasive Imaging of PSMA in Prostate Tumors with 89Zr-Labeled huJ591 Engineered Antibody Fragments: The Faster Alternatives
Nerissa Therese Viola-Villegas et al.
MOLECULAR PHARMACEUTICS (2014)
Comparative analysis of monoclonal antibodies against prostate-specific membrane antigen (PSMA)
J. Tykvart et al.
PROSTATE (2014)
Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer
Matthias Eder et al.
PHARMACEUTICALS (2014)
Synthesis, Radiolabelling and In Vitro Characterization of the Gallium-68-, Yttrium-90- and Lutetium-177-Labelled PSMA Ligand, CHX-A-DTPA-DUPA-Pep
Benjamin Baur et al.
PHARMACEUTICALS (2014)
Synthesis and SAR of 99mTc/Re-labeled small molecule prostate specific membrane antigen inhibitors with novel polar chelates
Genliang Lu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Targeting prostate cancer cells with PSMA inhibitor-guided gold nanoparticles
Benjamin B. Kasten et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Tumor-Receptor Imaging in Breast Cancer: A Tool for Patient Selection and Response Monitoring
S. Heskamp et al.
CURRENT MOLECULAR MEDICINE (2013)
PSMA as a target for radiolabelled small molecules
Matthias Eder et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)
99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen for Molecular Imaging of Prostate Cancer
Shawn M. Hillier et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Prostate-specific membrane antigen-based imaging
Joseph R. Osborne et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2013)
68Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging
Matthias Eder et al.
BIOCONJUGATE CHEMISTRY (2012)
Prostate-Specific Membrane Antigen-Based Therapeutics
Naveed H. Akhtar et al.
ADVANCES IN UROLOGY (2012)
Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen
Michael J. Evans et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Novel Polar Single Amino Acid Chelates for Technetium-99m Tricarbonyl-Based Radiopharmaceuticals with Enhanced Renal Clearance: Application to Octreotide
Kevin P. Maresca et al.
BIOCONJUGATE CHEMISTRY (2010)
Influence of Labelling Methods on Biodistribution and Imaging Properties of Radiolabelled Peptides for Visualisation of Molecular Therapeutic Targets
V. Tolmachev et al.
CURRENT MEDICINAL CHEMISTRY (2010)
'Image and treat': an individualized approach to urological tumors
Kirsten Bouchelouche et al.
CURRENT OPINION IN ONCOLOGY (2010)
Phase I dose-escalation study of docetaxel/predisone and fractionated 177Lu-J591 for metastatic castrate-resistant prostate cancer (metCRPC)
H. Beltran et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
68Ga-Labeled Inhibitors of Prostate-Specific Membrane Antigen (PSMA) for Imaging Prostate Cancer
Sangeeta Ray Banerjee et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
89Zr-DFO-J591 for ImmunoPET of Prostate-Specific Membrane Antigen Expression In Vivo
Jason P. Holland et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
High-Resolution Animal PET Imaging of Prostate Cancer Xenografts with Three Different 64Cu-Labeled Antibodies against Native Cell-Adherent PSMA
Karen Alt et al.
PROSTATE (2010)
Targeted Therapies for Prostate Cancer Against the Prostate Specific Membrane Antigen
U. Elsaesser-Beile et al.
CURRENT DRUG TARGETS (2009)
A modeling analysis of the effects of molecular size and binding affinity on tumor targeting
Michael M. Schmidt et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Biorecognition and Subcellular Trafficking of HPMA Copolymer-Anti-PSMA Antibody Conjugates by Prostate Cancer Cells
Jihua Liu et al.
MOLECULAR PHARMACEUTICS (2009)
Imaging techniques for prostate cancer: implications for focal therapy
Baris Turkbey et al.
NATURE REVIEWS UROLOGY (2009)
Preclinical Evaluation of a Monoclonal Antibody (3C6) Specific for Prostate-Specific Membrane Antigen
C. A. S. Regino et al.
CURRENT RADIOPHARMACEUTICALS (2009)
N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC:: A new imaging probe for prostate cancer
Ronnie C. Mease et al.
CLINICAL CANCER RESEARCH (2008)
Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors
Matthew I. Milowsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Technology Insight: monoclonal antibody imaging of prostate cancer
NH Bander
NATURE CLINICAL PRACTICE UROLOGY (2006)
Recent developments and future trends in nuclear medicine instrumentation
Habib Zaidi
ZEITSCHRIFT FUR MEDIZINISCHE PHYSIK (2006)
NAAG peptidase inhibitors and their potential for diagnosis and therapy
J Zhou et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer
NH Bander et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Imaging with radiolabelled monoclonal antibody (MUJ591) to prostate-specific membrane antigen in staging of clinically localized prostatic carcinoma: comparison with clinical, surgical and histological staging
V Nargund et al.
BJU INTERNATIONAL (2005)
Impact of fusion of indium-III Capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer
CJ Schettino et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2004)
Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen
NH Bander et al.
JOURNAL OF UROLOGY (2003)
The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy
N Schülke et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen
SA Rajasekaran et al.
MOLECULAR BIOLOGY OF THE CELL (2003)
Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and (90)yttrium-DOTA-peptide-ChL6
RT O'Donnell et al.
PROSTATE (2002)
Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase)
AP Kozikowski et al.
JOURNAL OF MEDICINAL CHEMISTRY (2001)
Share Paper
